NasdaqGS - Nasdaq Real Time Price USD

Design Therapeutics, Inc. (DSGN)

4.6500

-0.0600

(-1.27%)

At close: 4:00:01 PM EDT

4.6500

0.00

(0.00%)

After hours: 4:20:00 PM EDT

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

Building on the trial outcomes, Design is planning a Phase II biomarker trial of the eye drops.

Clinical Trials Arena 10 hours ago

DSGN
-1.27%
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park City 2025, an event ba

GlobeNewswire yesterday

DSGN
-1.27%
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and mul

GlobeNewswire 11 days ago

DSGN
-1.27%
April 2025's Promising Penny Stocks

Over the last 7 days, the market has remained flat, but it is up 5.7% over the past year, with earnings forecast to grow by 13% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when backed by solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, offering investors a chance to uncover hidden value in...

Simply Wall St. 14 days ago

DSGN
-1.27%

QD

KOD
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. “We are th

GlobeNewswire 15 days ago

DSGN
-1.27%
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. “John brings decades of experience and an extens

GlobeNewswire 15 days ago

XERS

DSGN
-1.27%

ANAB
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

DSGN
-1.27%
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of 2025; Enrollment Target Achieved in Fuchs Endothelial Corneal Dystrophy (FECD) Observational Study Selection of Development Candidate for Myotonic Dystrophy Type-1 (DM1) Expected in 2025 Well-Capitalized with Cash and Securities of $245.5 Million to Fund Opera

GlobeNewswire last month

DSGN
-1.27%
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.

GlobeNewswire last month

DSGN
-1.27%
US Penny Stocks To Watch In February 2025

As the S&P 500 reaches record highs, major stock indexes in the United States continue to show resilience and growth. In this context, penny stocks—though often seen as relics of a bygone era—remain relevant for investors seeking opportunities in smaller or less-established companies. By focusing on those with strong financials and potential for growth, these stocks can offer value and stability.

Simply Wall St. 2 months ago

DSGN
-1.27%

ABCL

NVTS
3 Promising US Penny Stocks With Market Caps Under $900M

As the U.S. stock market continues to rally following President Trump's return to office, investors are closely watching the impact of new policies on various sectors. In this context, penny stocks remain an intriguing area for those looking for potential growth opportunities. Though often associated with speculative trading, these smaller or newer companies can offer significant returns when they possess strong financial fundamentals. We'll highlight three such penny stocks that stand out...

Simply Wall St. 3 months ago

NVTS

ABCL

DSGN
-1.27%
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3,

GlobeNewswire 5 months ago

DSGN
-1.27%
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Se

GlobeNewswire 5 months ago

DSGN
-1.27%
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Design...

Simply Wall St. 5 months ago

DSGN
-1.27%
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 7 months ago

DSGN
-1.27%
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The

GlobeNewswire 7 months ago

DSGN
-1.27%
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 8 months ago

DSGN
-1.27%
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Key Insights Institutions' substantial holdings in Design Therapeutics implies that they have significant influence...

Simply Wall St. 8 months ago

DSGN
-1.27%
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments

GlobeNewswire 8 months ago

DSGN
-1.27%
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:PIPR) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. Piper Sandler may be the best bet for investors especially when you see

InvestorPlace 11 months ago

CNTX

RVNC

ABBV

Performance Overview

Return	DSGN	S&P 500 (^GSPC)
YTD	-24.64%	-3.31%
1-Year	+27.40%	+12.29%
3-Year	-62.62%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Design Therapeutics, Inc. (DSGN)

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 2025's Promising Penny Stocks

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

US Penny Stocks To Watch In February 2025

3 Promising US Penny Stocks With Market Caps Under $900M

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Performance Overview